Novel Quinoline-Based P2–P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors

[Image: see text] We have previously reported the discovery of our P2–P4 macrocyclic HCV NS3/4a protease inhibitor MK-5172, which in combination with the NS5a inhibitor MK-8742 recently received a breakthrough therapy designation from the US FDA for treatment of chronic HCV infection. Our goal for t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shah, Unmesh, Jayne, Charles, Chackalamannil, Samuel, Velázquez, Francisco, Guo, Zhuyan, Buevich, Alexei, Howe, John A., Chase, Robert, Soriano, Aileen, Agrawal, Sony, Rudd, Michael T., McCauley, John A., Liverton, Nigel J., Romano, Joseph, Bush, Kimberly, Coleman, Paul J., Grisé-Bard, Christiane, Brochu, Marie-Christine, Charron, Sylvie, Aulakh, Virender, Bachand, Benoit, Beaulieu, Patrick, Zaghdane, Helmi, Bhat, Sathesh, Han, Yongxin, Vacca, Joseph P., Davies, Ian W., Weber, Ann E., Venkatraman, Srikanth
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2014
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4027630/
https://ncbi.nlm.nih.gov/pubmed/24900818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml400466p
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados